# Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic C

Source: https://onco.cc/trials/nct04827953/  
OnCo record `nct04827953` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Nelum Corp, active and no longer recruiting.

## Summary

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer is a phase 1/2 interventional study registered as NCT04827953 by Nelum Corp, with 28 participants enrolled, started 2021-09-01 and due to reach its primary completion in 2025-04. Interventions recorded: Gemcitabine, Nab paclitaxel, NLM-001, Zalifrelimab. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04827953
- Phase: 1/2
- Setting: Phase Ib/IIa Study to Evaluate Safety and Efficacy of Treatment With the Hedgehog Inhibitor NLM-001 and Chemotherapy (Gemcitabine and Nab-Paclitaxel) Plus Zalifrelimab as First Line Treatment in Patients With Advanced Pancreatic Cancer
- Sponsor: Nelum Corp
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT04827953: https://clinicaltrials.gov/study/NCT04827953

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Zalifrelimab](https://onco.cc/drugs/zalifrelimab/)

---
JSON: https://onco.cc/api/v1/entities/nct04827953.json